Treosulfan/Fludarabine Conditioning Improves Outcomes in HSCT

A recent phase 3 trial found that treosulfan/fludarabine used as conditioning treatment prior to allogeneic hematopoietic stem cell transplantation (HSCT) led to greater event-free survival compared with busulfan/fludarabine in older or comorbid patients with acute myeloid leukemia or myelodysplastic syndrome. While patients age 50 or older with acute myeloid leukemia or myelodysplastic syndrome are often considered eligible for allogeneic HSCT, they are at increased risk from standard myeloabla...
Continue reading

Ibrutinib Increases Hypertension and Cardiovascular Risk

For patients with B-cell malignancies, the hypertension caused or worsened by treatment with ibrutinib results in a two-fold increased risk of major adverse cardiovascular events, report researchers at The Ohio State University. Ibrutinib can be highly effective against B-cell malignancies such as mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenstrom macroglobulinemia. However, it also is associated with cardiotoxicity. Severe hypertension has been reported, but "the long-term inci...
Continue reading

Treating Multiple Myeloma: Challenges, Solutions, and Research Advances With Carol Ann Huff, MD

​ With a five-year survival rate of only 50.7%, multiple myeloma remains difficult to treat. In this interview with i3 Health, Carol Ann Huff, MD, Medical Director for the Johns Hopkins Kimmel Cancer Center, explores the challenges and research advances of myeloma treatment. She also gives advice on helping patients to find assistance with the prohibitive costs of treatment and on handling the difficulties involved in treating patients at smaller community cancer centers, including patients who ...
Continue reading

When Should Ruxolitinib Be Used for Myelofibrosis or PV? With Srdan Verstovsek, MD, PhD

Myelofibrosis, a rare myeloproliferative neoplasm, can cause severe anemia, splenomegaly, and debilitating symptoms. It can present either as a primary condition or as a secondary condition following the transformation of essential thrombocythemia or polycythemia vera (PV), a slow-growing blood cancer in which the bone marrow produces an excess of red blood cells and often of white blood cells and platelets. Last week at the Society of Hematologic Oncology (SOHO)'s Seventh Annual Meeting, Srdan ...
Continue reading

Bortezomib/Lenalidomide/Dexamethasone for Multiple Myeloma

​ A phase 3 trial reports that a combined regimen of subcutaneous bortezomib, lenalidomide, and dexamethasone (VRD) is effective as induction therapy prior to autologous stem cell transplant (autoSCT) in newly diagnosed multiple myeloma, with responses that strengthen over time. "Achieving and maintaining high-quality response is the treatment goal for patients with newly diagnosed multiple myeloma," state the researchers in their publication in Blood , led by first author Laura Rosiñol, MD, PhD...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.